Auteur : GRECC

The Past and Future of Psychedelic Science : An Introduction to This Issue, Richard E. Doblin et al., 2019

The Past and Future of Psychedelic Science : An Introduction to This Issue Richard E. Doblin, Merete Christiansen, Lisa Jerome, Brad Burge JOURNAL OF PSYCHOACTIVE DRUGS, 2019, VOL. 51, NO. 2, 93–97 https://doi.org/10.1080/02791072.2019.1606472   ABSTRACT Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of scientific and cultural exploration in the1950s and ‘60s, psychedelic research was [...]

Lire la suite

Can Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect ?, Jacob S. Aday et al., 2019

Can Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect ? Jacob S. Aday, Emily K. Bloesch, & Christopher C. Davoli Journal of Cognitive Enhancement, August 2019 DOI: 10.1007/s41465-019-00151-6   Abstract Older adulthood can be characterized by various cognitive and affective changes. In general, older adults show declines in creativity and executive functioning. They also score lower in openness to experience, empathy, and many suffer from a paucity of meaningful experiences. Further, depression, pessimism, and suicide can be major concerns for this population. Although currently there are few interventions that can effectively address these changes, recent findings from psychedelic science suggest myriad parallels between the effects [...]

Lire la suite

Clinicians’ Guide to Cannabidiol and Hemp Oils, Harrison J. VanDolah et al., 2019

Clinicians’ Guide to Cannabidiol and Hemp Oils Harrison J. VanDolah, Brent A. Bauer, and Karen F. Mauck  Mayo Clinic Proceedings, 2019, 94, (9), 1840-1851 https://doi.org/10.1016/j.mayocp.2019.01.003   Abstract Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. Patients report relief for a variety of conditions, particularly pain, without the intoxicating adverse effects of medical marijuana. In June 2018, the first CBD-based drug, Epidiolex, was approved by the US Food and Drug Administration for treatment of rare, severe epilepsy, further putting the spotlight on CBD and hemp oils. There is a growing body of preclinical and [...]

Lire la suite

Switch to mania after ayahuasca consumption in a man with bipolar disorder : a case report, Alejandro G Szmulewicz et al., 2015

Switch to mania after ayahuasca consumption in a man with bipolar disorder : a case report Alejandro G Szmulewicz, Marina P Valerio and Jose M Smith International Journal of Bipolar Disorders, 2015, 3, (4), 1-3. DOI 10.1186/s40345-014-0020-y   Abstract Background : There is an increasing use of ayahuasca for recreational purposes. Furthermore, there is a growing evidence for the antidepressant properties of its components. However, there are no reports on the effects of this substance in the psychiatric setting. Harmaline, one of the main components of ayahuasca, is a selective and reversible MAO-A inhibitor and a serotonin reuptake inhibitor. Case report : We present the case of [...]

Lire la suite

2018 : A Watershed Year for Psychedelic Science ?, Jacob S. Aday et al., 2019

2018 : A Watershed Year for Psychedelic Science ? Jacob S. Aday, Christopher C. Davoli, & Emily K. Bloesch Article, ·August 2019 DOI: 10.1177/2050324519872284 Abstract While interest in the study of psychedelic drugs has increased over much of the last decade, in this article we argue that 2018 marked the true turning point for the field. Substantive advances in the scientific, public, and regulatory communities in 2018 significantly elevated the status and long-term outlook of psychedelic science, particularly in the United States. Advances in the scientific community can be attributed to impactful research applications of psychedelics as well as acknowledgement in preeminent journals. In the [...]

Lire la suite

SALVIA DIVINORUM AND SALVINORIN A , The Best of The Entheogen Review, David Aardvark,1999-2000

SALVIA DIVINORUM AND SALVINORIN A The Best of The Entheogen Review David Aardvark, Editor ER MONOGRAPH SERIES, NO. 2, 1992–2000, Second Edition The Entheogen Review POB 19820 Sacramento, CA 95819-0820 TABLE OF CONTENTS A NOTE ON THE TEXT 9 CHAPTER ONE : The Early Years 11 CHAPTER TWO : Consumption Methods 21 CHAPTER THREE : Hyperspatial Maps 45 CHAPTER FOUR : Extraction 73 CHAPTER FIVE : Salvinorin A & More 81 CHAPTER SIX : Combinations 103 CHAPTER SEVEN : Cultivation 113 CHAPTER EIGHT : Reviews, Interviews, Commentary & Press 133 APPENDIX A : Sources 171 APPENDIX B : The Internet 185 ANNOTATED BIBLIOGRAPHY 197 INDEX 231 ACKNOWLEDGMENTS 249 A NOTE ON THE TEXT Most of the information presented herein comes from the first [...]

Lire la suite

Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine, Samuel T. Wilkinson et al., 2019

Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine Samuel T. Wilkinson, David H. Howard,  Susan H. Busch JAMA Published online August 2, 2019 doi:10.1001/jama.2019.10728   Major depressive disorder (MDD) affects approximately 17.3 million adults in the United States,1 with a 12-month and lifetime prevalence of 10.4% and 20.6%, respectively.2 Conducting clinical trials and developing new treatments for depression can be difficult because of spontaneous recovery rates and placebo effects.3 In addition, many patients with chronic and refractory MDD do not experience clinical improvement even after several treatment courses. There is growing interest in the use of exercise and improved nutrition to treat depression,4 [...]

Lire la suite

Heaven and Hell Revisited, Peter Webster, 1996

Heaven and Hell Revisited Peter Webster Composed in 1996 for The Psychedelic Library   How is it possible for two persons of such obvious intellectual talent as William Braden and Aldous Huxley to have such radically different experiences as a result of ingestion of a similar quantity of mescaline? Both Huxley and Braden brought to their first psychedelic experiment a wide knowledge and understanding of science, religion, mysticism, literature and fine arts, yet Huxley’s initial psychedelic experience was a revelation, and led to the writing of The Doors of Perception, a book which launched a movement, if not a revolution. William Braden’s experiment, recounted [...]

Lire la suite

From local to global—Fifty years of research on Salvia divinorum, Ivan Casselman et al., 2014

From local to global—Fifty years of research on Salvia divinorum Ivan Casselman, Catherine J. Nock, Hans Wohlmuth, Robert P. Weatherby, Michael Heinrich Journal of Ethnopharmacology, 2014, 151, 768–783 http://dx.doi.org/10.1016/j.jep.2013.11.032   a b s t r a c t Ethnopharmacological relevance : In 1962 ethnopharmacologists, Hofmann and Wasson, undertook an expedition to Oaxaca,Mexico. These two researchers were the first scientists to collecta flowering specimen of Salvia divinorum allowing theidentification ofthisspecies.Whilet he species'traditional use is confined to a very small region of Mexico, since Hofmann and Wasson's expedition 50 years ago, Salvia divinorum has become globally recognized for its main active constituent, the diterpene salvinorin A, which has [...]

Lire la suite

Psychedelics and the new behaviourism : considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy, Zach Walsh and Michelle S. Thiessen, 2018

Psychedelics and the new behaviourism : considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy REVIEW ARTICLE Zach Walsh and Michelle S. Thiessen INTERNATIONAL REVIEW OF PSYCHIATRY, 2018. https://doi.org/10.1080/09540261.2018.1474088   ABSTRACT This narrative review examines evidence related to the potential for third wave behaviour therapies to serve as adjuncts to psychedelic-assisted therapy. It identifies shared theoretical foundations for both approaches, and notes enhanced mindfulness, decentering, emotion regulation, and distress tolerance as common mechanisms of action. It also identifies potential targets for which both approaches have demonstrated therapeutic potential, including problematic substance use, self-directed and other directed violence, and mood disorders. Based on these commonalities, there is [...]

Lire la suite